back to news

Valneva Reports Successful Outcome of Phase 2 Run-In for its Lyme Disease Vaccine Candidate


Based on DSMB clearance, two lead dosage levels have been selected for ongoing Phase 2 clinical development

Saint-Herblain (France), June 12, 2019 – Valneva SE (“Valneva” or “the Company”), a biotech company developing and commercializing vaccines for infectious diseases with major unmet medical needs, today announced progress of its ongoing Phase 2 study for its leading, unique Lyme disease vaccine candidate, VLA15, into the main study phase. An independent Data Safety Monitoring Board (DSMB) has cleared two dosage levels to be used for clinical development.

Valneva has previously reported initial booster data and final Phase 1 follow-up data for VLA15, confirming that the vaccine candidate has a favorable safety profile and was immunogenic in all doses and formulations tested. VLA15 elicited an excellent anamnestic response following a booster vaccination in a time window of 12 to 15 months after initial primary immunization1.

As part of the VLA15-201 run-in Phase, 120 subjects received one of three alum adjuvanted dose levels of VLA15 (90µg, the high dose from Phase 1, 135µg or 180µg) or placebo. The DSMB has reviewed safety data from those subjects and has cleared the 135µg and 180µg dosage levels for further investigation in the main study phase.

Valneva has commenced preparations to initiate a further Phase 2 study (VLA15-202) to evaluate an alternative immunization schedule. The Company expects this study to commence in the third quarter of this year.

Wolfgang Bender, MD, PhD, Chief Medical Officer of Valneva, commented, “We are pleased that the run-in safety data confirm our hypothesis that we can proceed with higher doses than initially studied in Phase 1. Given the well-understood mode of action, high anti-OspA antibody titers are key to deliver a highly effective vaccine that will address the significant unmet medical need arising from the increasing spread of Lyme disease”.

Preliminary Phase 2 results (primary endpoint) are anticipated – as previously announced – mid-2020.

About The Phase 2 Clinical Study VLA15-201

VLA15-201 is the first of two planned, parallel Phase 2 studies. It is a randomized, observer- blind, placebo controlled trial conducted at trial sites in the US and Europe. In the run-in Phase, 120 subjects received one of three dosage levels of VLA15, or placebo. Following review of safety data by an independent Data Safety Monitoring Board, 450 subjects in the main study phase will receive one of two selected dose levels of VLA15 (180 subjects each), or placebo (90 subjects).

VLA15 will be tested as alum adjuvanted formulation and will be administered intramuscularly in three injections, given one month apart at Days 1, 29 and 57. Subjects will be followed for one year, with the main immunogenicity readout one month after the third immunization on Day 85 (Primary Endpoint). The study is enrolling healthy adults 18 to 65 years of age. Study centers will be located in areas where Lyme disease is endemic; subjects with a cleared past infection with Borrelia burgdorferi, the bacteria that cause Lyme disease, will also be enrolled.

About Lyme Disease

Lyme disease is a systemic infection caused by Borrelia bacteria transmitted to humans by infected Ixodes ticks2. It is considered the most common vector borne illness in the Northern Hemisphere. According to the U.S. Centers for Disease Control and Prevention (CDC), approximately 300,000 Americans3 are diagnosed with Lyme disease each year with at least a further 200,000 cases in Europe4. Early symptoms of Lyme disease (such as a gradually expanding erythematous rash called Erythema migrans or more unspecific symptoms like fatigue, fever, headache, mild stiff neck, arthralgia or myalgia) are often overlooked or misinterpreted. Left untreated, the disease can disseminate and cause more serious complications affecting the joints (arthritis), the heart (carditis) or the nervous system. The medical need for vaccination against Lyme disease is steadily increasing as the disease footprint widens5.

About VLA15

Valneva’s vaccine candidate, VLA15, is currently the only active vaccine program in clinical development against Lyme disease. The program was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) in July 20176 and Valneva reported positive Phase

1 results in March 20187. VLA15 showed a favourable safety profile and was immunogenic in all doses and formulations tested with good OspA-specific IgG antibody responses against all OspA serotypes.

VLA15 is a multivalent, protein subunit vaccine that targets the outer surface protein A (OspA) of Borrelia. It is designed for prophylactic, active immunization against Lyme disease aiming for protection against the majority of human pathogenic Borrelia species. VLA15 is designed to confer protection by raising antibodies that prevent Borreliae from migrating from ticks to humans after a bite. The safety profile is expected to be similar to other lipidated protein based vaccines that are approved for active immunization in adults and children

The target population includes individuals at risk above 2 years of age living in endemic areas, people planning to travel to endemic areas to pursue outdoor activities and people at risk who have a history of Lyme disease (as infection with Borrelia does not confer protective immunity against all pathogenic Borrelia species).